
brief_title: Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
official_title: A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
brief_summary:
 This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in
 patients with advanced solid tumors.
inclusion_criteria:
 - confirmed diagnosis of advanced solid tumor (including â€¢medulloblastoma and basal cell carcinoma Sense3 ) - blood work criteria
exclusion_criteria:
 - patients with history of brain tumor (except recurrent medulloblastoma) or brain metastases - positive HIV, hepatitis B or C - impaired intestinal function - impaired heart function - pregnant or breast-feeding women Other protocol-defined inclusion/exclusion criteria may apply

===============

Study number 36

study_id:  